Skip to main content
SpringerLink
Log in

Lessons Learned

  • Chapter
Data Monitoring in Clinical Trials

  • 1354 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Canner PL. 1983. Monitoring of the data for evidence of adverse or beneficial treatment effects in the Coronary Drug Project. Control Clin Trials 4:467–483.

    Article  Google Scholar 

  2. DeMets D. 1984. Stopping guidelines vs. stopping rules: A practitioner’s point of view. Commun Statist-Theor Meth A 13:2395–2417.

    Article  Google Scholar 

  3. Fleming T, DeMets DL. 1993. Monitoring of clinical trials: issues and recommendations. Control Clin Trials 14:183–197.

    Article  Google Scholar 

  4. Pocock SJ. 1992. When to stop a clinical trial. BMJ 305:235–240.

    Article  Google Scholar 

  5. The Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group. 1994. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 330:1029–1035.

    Article  Google Scholar 

  6. The World Medical Association. World Medical Association Declaration of Helsinki: Ethical principals for medical research involving human subjects. October 2000 amended version, with 2002 clarification. http://www.wma.net/e/policy/b3.htm.

    Google Scholar 

  7. Dickersin K, Chan S, Chalmers TC, Sacks HS, Smith H Jr. 1987. Publication bias and clinical trials. Control Clin Trials 8:343–353.

    Article  Google Scholar 

  8. Ioannidis JPA. 1998. Effect of the statistical significance of results on the time to completion and publication of randomized efficacy trials. JAMA 279:281–286.

    Article  Google Scholar 

  9. Thackray S, Witte K, Clark AL, Cleland JGF. 2000. Clinical trials update: OPTIME-CHF, PRAISE-2, ALL-HAT. Eur J Heart Fail 2:209–212.

    Article  Google Scholar 

  10. Kahn JO, Cherng DW, Mayer K, Murray H, Lagakos S for the 806 Investigator Team. 2000. Evaluation of HIV-1 Immunogen, an immunologic modifier, administered to patients infected with HIV having 300 to 549 x 106/L CD4 cell counts: a randomized controlled trial. JAMA 284:2193–2202.

    Article  Google Scholar 

  11. DeAngelis CD. 2000. Conflict of Interest and the Public Trust (editorial). JAMA 284:2237–2238.

    Article  Google Scholar 

  12. Berson EL, Rosner B, Sandberg MA, Hayes KC, Nicholson BW, Weigel-DiFranco C, Willett W. 1993. A randomized trial of vitamin A and vitamin E supplementation for retinitis pigmentosa. Arch Ophthalmol 111:761–772.

    Article  Google Scholar 

  13. Norton EWD. 1993. Letter to the editor. Arch Ophthalmol 111:1460.

    Article  Google Scholar 

  14. Marmor MF. 1993. Letter to the editor. Arch Ophthalmol 111:1460–1461.

    Article  Google Scholar 

  15. Berson EL, Rosner B, Sandberg MA, Hayes KC, Nicholson BW, Weigel-DiFranco C, Willett C. 1993. Letter to the editor. Arch Ophthalmol 11:1463–1465.

    Article  Google Scholar 

  16. Dahlof B, Devereux R, de Faire U, Fyhrquist F, Hedner T, et al. 1997. The Losartan Intervention For Endpoint reduction (LIFE) in hypertension study: rationale, design, and methods. The LIFE Study Group. Am J Hypertens 10:705–713.

    Article  Google Scholar 

  17. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. 2002. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 359:995–1003.

    Article  Google Scholar 

  18. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, et al. 2004. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350:1495–1504.

    Article  Google Scholar 

  19. Chen YHJ, DeMets DL, Lan KKG. 2003. Monitoring mortality at interim analyses while testing a composite endpoint at the final analysis. Control Clin Trials 24:16–27.

    Article  Google Scholar 

  20. Writing Group for the Women’s Health Initiative Randomized Controlled Trial. 2002. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 288:321–333.

    Article  Google Scholar 

  21. The Women’s Health Initiative Steering Committee. 2004. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. The Women’s Health Initiative Randomized Controlled Trial. JAMA 291:1701–1712.

    Article  Google Scholar 

  22. Freedman L, Anderson G, Kipnis V, Prentice R, Wang CY, Rossouw J, Wittes J, DeMets D. 1996. Approaches to monitoring the results of long-term disease prevention trials: Examples from the Women’s Health Initiative. Control Clin Trials 17:509–525.

    Article  Google Scholar 

  23. National Emphysema Treatment Trial Research Group. 2001. Patients at high risk of death after lung-volume-reduction surgery. N Engl J Med 345:1075–1083.

    Article  Google Scholar 

  24. Lee SM, Wise R, Sternberg AL, Tonascia J, Piantadosi S, for the National Emphysema Treatment Trial Research Group. 2004. Methodologic isssues in terminating enrollment of a subgroup of patients in a multicenter randomized trial. Clin Trials 1:326–338.

    Article  Google Scholar 

  25. National Emphysema Treatment Trial Research Group. 2003. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med 348:2059–2073.

    Article  Google Scholar 

  26. Packer M, O’Connor CM, Ghali JK, Pressler ML, Carson PE, et al. 1996. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. N Engl J Med 335:1107–1114.

    Article  Google Scholar 

  27. Prentice RL. 1989. Surrogate endpoints in clinical trials: Definition and operational criteria. Stat Med 8:431–440.

    Article  Google Scholar 

  28. Fleming TR, DeMets DL. 1996. Surrogate end points in clinical trials: are we being misled? Ann Intern Med 125:605–613.

    Google Scholar 

  29. Norwegian Multicenter Study Group. 1981. Timolol induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 304:801–807.

    Article  Google Scholar 

  30. CIBIS II Investigators and Committees. 1999. The Cardiac Insufficiency Bisoprolol Study II (CIBIS II): A randomised trial. Lancet 353:9–13.

    Article  Google Scholar 

  31. The Multiple Risk Factor Intervention Trial Research Group. 1990. Mortality rates after 10.5 years for participants in the Multiple Risk Factor Intervention Trial. Findings related to a priori hypotheses of the trial. JAMA 263:1795–1801.

    Article  Google Scholar 

  32. Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, et al. 2002. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 288:49–57.

    Article  Google Scholar 

  33. Black HR, Elliott WJ, Grandits G, Grambsch P, Lucente T, White WB, et al. 2003. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA 289:2073–2082.

    Article  Google Scholar 

  34. Psaty BM, Rennie D. 2003. Stopping medical research to save money. A broken pact with researchers and patients. JAMA 289:2128–2131.

    Article  Google Scholar 

  35. Boyd K. 2001. Commentary: Early discontinuation violates Helsinki principles. BMJ 322:605–606.

    Google Scholar 

  36. Food and Drug Administration, Department of Health and Human Services. 1998. International Conference on Harmonisation: Guidance on statistical principles for clinical trials; availability. Federal Register Vol 63, No 179:49583–98. http://www.fda.gov/cber/gdlns/ichclinical.pdf.

    Google Scholar 

  37. Armstrong PW, Newby LK, Granger CB, Lee KL, Simes J, Van de Werf F, White HD, Califf RM for the Virtual Coordinating Centre for Global Collaborative Cardiovascular Research (VIGOUR) Group. 2004. Lessons learned from a clinical trial. Circulation 110:3610–3614.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Biostatistics and Medical Informatics, University of Wisconsin, Madison, Wisconsin

    David L. DeMets

  2. Department of Public Health Sciences, Wake Forest University School of Medicine, Winston-Salem, North Carolina

    Curt D. Furberg

  3. Bethesda, Maryland

    Lawrence M. Friedman

Authors
  1. David L. DeMets
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Curt D. Furberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lawrence M. Friedman
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Biostatistics and Medical Informatics, University of Wisconsin Medical School, Madison, WI, 53972-4675, USA

    David L. DeMets

  2. Department of Public Health Sciences, Wake Forest University School of Medicine, Winston-Salem, NC, 27157, USA

    Curt D. Furberg

  3. Bethesda, MD, USA

    Lawrence M. Friedman

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Springer Science+Business Media, Inc.

About this chapter

Cite this chapter

DeMets, D.L., Furberg, C.D., Friedman, L.M. (2006). Lessons Learned. In: DeMets, D.L., Furberg, C.D., Friedman, L.M. (eds) Data Monitoring in Clinical Trials. Springer, New York, NY. https://doi.org/10.1007/0-387-30107-0_2

Download citation

Publish with us

Policies and ethics

Search

Navigation